I think the justification for the current work will be “planning” the next Gen pathway. Then enter very dilutive funding ( sub 1c) from the C14 work and the merry-ago-around continues.
The annual report backs this up:
· The results from BIT225 have important implications for Biotron’s other antiviral programs targeting other viruses as they support the druggability of this new class of drugs
· Good progress continued with early-stage programs, in particular Hepatitis B virus and Dengue virus
Noting the report also says:
· The US-based C14 Consulting Group, LLC has been appointed to work with Biotron to refine its commercialisation strategy and provide business development support
Hence C14 is not necessarily looking for a buyer.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.654M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $210 | 104.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 64 | 38848316 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 18281126 | 25 |
View Market Depth
| Last trade - 12.28pm 27/06/2025 (20 minute delay) ? |
| BIT (ASX) Chart |